07.07.2022
reverSASP Therapeutics (Headquarters: Bunkyo City, Tokyo, Japan; hereinafter referred to as “reverSASP”) has announced their seed stage funding round totaling 600M JPY, jointly led by Fast Track Initiative (hereinafter referred to as “FTI”) and the University of Tokyo Collaborative Creation Platform Development (hereinafter referred to as the “University of Tokyo IPC”). FTI invests 300M JPY in this round.
reverSASP is a new biotech startup that is focusing its efforts on innovative new drugs for various aging-related diseases based on aging biology research by Dr. Makoto Nakanishi of the Institute of Medical Science at the University of Tokyo. Dr. Nakanishi is a leading expert in this field with numerous achievements including the elucidation of the properties of inflammatory senescent cells, which are known to be a root cause of age-related diseases.
FTI and the University of Tokyo IPC have been supporting reverSASP since before its establishment with Takashi Futami, Principal of FTI, as an external BoD and Keita Kiriya, Analyst at FTI, as Auditor. By providing treatment options for various intractable diseases and satisfying unmet medical needs, FTI sees great potential in reverSASP to contribute to the health and medical care of people around the world, helping to make human aging a more manageable life process in the future.
About reverSASP Therapeutics:
reverSASP Therapeutics is a biotech startup founded in early 2022, working on novel drug discovery through aging biology based on new elucidation of cellular senescence cells and its relationship to various age-related diseases. It aims to addresses social issues caused by the declining birthrate and aging population by extending healthy life expectancy and envisions a world where people can live in good health until the end of their lives without relying on nursing care. Visit https://www.reversasp.com for more details.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on grow seed and early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including diagnostics, digital health, healthcare services, and more. The company provides full, hands-on operational support to its 30+ portfolio companies through business and R&D strategy, investor syndication, and more, including access to its exclusive network of leading industry professionals in Japan. Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/. For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
